Literature DB >> 2379594

Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases.

P Schlag1, P Hohenberger, C Herfarth.   

Abstract

One hundred and twenty-two patients underwent liver resection for metastases of colorectal cancer within 8 years. Seventy-four of them were treated for metachronous metastases detected in a median of 18 months after resection of the primary tumor. In another 48 patients the metastases were resected at the same time as the primary cancer. Both groups were analysed for disease-free and overall survival, and for peri-operative morbidity. However, neither the type of hepatic resection nor peri-operative morbidity showed relevant differences in the groups, except for the metachronous group, the only group in which operative mortality occurred (6.7%). Survival was not significantly different, being 32 months in the metachronous and 24 months in the synchronous groups (P = 0.051). However, disease-free survival showed significant differences; no patient in the synchronous group experienced a recurrence-free interval of more than 3 years. The median time interval until diagnosis of a recurrence was 10 months after resection of metachronous metastases, but only 6 months in the synchronous group (P = 0.018). The pattern of recurrence showed a much higher proportion of patients with disseminated disease in the synchronous group (95% vs 42%). Therefore, liver resection in synchronous colorectal metastases should be handled very restrictively and adjuvant treatment strategies considered in the future.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379594

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  43 in total

1.  Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.

Authors:  Eduardo de Santibañes; Diego Fernandez; Carlos Vaccaro; Guillermo Ojea Quintana; Fernando Bonadeo; Juan Pekolj; Carlos Bonofiglio; Ernesto Molmenti
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 2.  Treatment options for colorectal liver metastases.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

Review 3.  Resection of colorectal liver metastases revisited.

Authors:  J Scheele; C Rudroff; A Altendorf-Hofmann
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 4.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

5.  Should hepatic resections be performed at high-volume referral centers?

Authors:  M A Choti; H M Bowman; H A Pitt; J A Sosa; J V Sitzmann; J L Cameron; T A Gordon
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.452

6.  What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up.

Authors:  Carlo Pulitanò; Federico Castillo; Luca Aldrighetti; Martin Bodingbauer; Rowan W Parks; Gianfranco Ferla; Stephen J Wigmore; O James Garden
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

Review 7.  Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.

Authors:  G Scott Gazelle; M G Myriam Hunink; Karen M Kuntz; Pamela M McMahon; Elkan F Halpern; Molly Beinfeld; Jessica S Lester; Kenneth K Tanabe; Milton C Weinstein
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

8.  Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases.

Authors:  Moritz Koch; Peter Kienle; Ulf Hinz; Dalibor Antolovic; Jan Schmidt; Christian Herfarth; Magnus von Knebel Doeberitz; Jürgen Weitz
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

9.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Authors:  Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

10.  Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

Authors:  D J Watkins; I Chau; D Cunningham; S S Mudan; N Karanjia; G Brown; S Ashley; A R Norman; A Gillbanks
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.